31 results about "Insulin-like growth factor binding" patented technology

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to screening or testing for insulin like growth factors, insulin like growth factor binding proteins and / or acid labile subunit by the use of a solid support. Blood is collected onto a solid support, such as paper, and subsequently the analytes of interest are extracted for testing.

The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.

The invention provides an SNP locus related to growth characteristics of patinopecten yessoensis. The locus is the 1054 site of IGFBP (Insulin Like Growth Factor Binding Proteins) genes of which the nucleotide sequence is shown as SEQ ID NO:2 and has the base of A or G. The invention also provides a probe for detecting the SNP locus and a parting primer. The transcription sequence of the IGFBP genes in the patinopecten yessoensis is subjected to sequencing and Clustal comparison, and three SNP loci are screened. The site polymorphism is detected in the patinopecten yessoensis group by using a high resolution melting curve technology, and correlation between the site genotype frequency and the growth characteristics of patinopecten yessoensis is analyzed. The locus C.1054A>G is obviously related to important growth characteristics such as the height, shell length, weight, soft weight and adductor muscle weight of the patinopecten yessoensis, the growth characteristics of the AG type individuals are obviously lower than those of AA and GG type individuals (P is less than 0.05), and the characteristic value of the GG type is the highest. Therefore, individuals of which the genotype is GG on the locus can be preferentially selected during production and are used as parents for performing high-yield patinopecten yessoensis breeding or performing large-scale breeding.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

The invention relates to the field of medical science, and provides a biomarker for hepatocellular carcinoma related detection, particularly a biomarker for detecting HBV related hepatocellular carcinoma. The biomarker comprises an insulin-like growth factor binding protein 7 (IGFBP7) and an alpha fetoprotein (AFP). A method for detecting hepatocellular carcinoma, based on the biomarker namely the IGFBP7 and the AFP, comprises a step of carrying out judgement by measuring a marker IGFBP7 gene promotor methylation level and detecting the sensitivity of the marker AFP for being combined with serum IGFBP7 gene promoter methylation. According to biomarker, the AFP is combined with the IGFBP7 gene promoter methylation, so that the traditional detection of single indexes is changed, and the efficiency of HCC diagnosis is increased.

An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and / or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and / or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury) / ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI / ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and / or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.

The invention discloses an application of insulin-like growth factor binding protein 5 (IGFBP5) in promotion of mesenchymal stem cell induced periodontal tissue regeneration.

The invention relates to an induced expression and purification method of a human-derived insulin-like growth factor binding protein 1 in pichia pastoris. A nucleotide sequence optimized by codons and used for coding the human-derived insulin-like growth factor binding protein 1 is connected with an HIS tag label, then is constructed into a pichia pastoris induced expression vector, next is transferred into pichia pastoris, and is subjected to induced expression; the expression product is subjected to affinity chromatography to obtain a purified human-derived insulin-like growth factor binding protein 1. The invention also relates to related antibodies and an application thereof in preparation of diagnostic kits for premature rupture of fetal membranes. The induced expression and purification method of the human-derived insulin-like growth factor binding protein 1 in pichia pastoris is skillful in design, and thus the human-derived insulin-like growth factor binding protein 1 can be efficiently expressed; and with the human-derived insulin-like growth factor binding protein 1 as an antigen, a high-specific polyclonal antibody and a high-specific monoclonal antibody for recognition of different IGFBP-1 epitopes are obtained, thereby laying the foundation for application of multiple downstream detection kits, and being suitable for large-scale popularization and application.

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

The invention relates to an application of an insulin-like growth factor binding protein 2 (IGFBP2) to the promotion of mesenchymal stem cell mediated adipose tissue regeneration. The invention furthermore relates to an application of the IGFBP2 to the preparation of drugs for promoting mesenchymal stem cell mediated adipose tissue regeneration, and an application of mesenchymal stem cells for IGFBP2 over-expression to the preparation of drugs for treating adipose tissue regeneration. According to the application, the research discovers that the IGFBP2 has the effect of promoting adipogenic differentiation of the mesenchymal stem cells, so that the adipose tissue regeneration capability of the mesenchymal stem cells can be enhanced by utilizing the IGFBP2, and the IGFBP2 can be predictably applied to the treatment and repair of congenital and acquired adipose tissue defects.

Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and / or survival by measuring the level of IGFBP-3R in tumor tissue are provided.

The invention provides application of insulin-like growth factor binding protein 2 in preparation of a postoperative prognosis evaluation kit for neuroendocrine carcinoma, the prognosis evaluation kitfor the neuroendocrine carcinoma and a prognosis evaluation method for the neuroendocrine carcinoma. Relative transcript level of the insulin-like growth factor binding protein 2 in neuroendocrine carcinoma tissues is detected according to an immunohistochemical method so as to judge relapse and metastasis risks of the neuroendocrine carcinoma of the neuroendocrine carcinoma patients. The application of the insulin-like growth factor binding protein 2 in preparation of the postoperative prognosis evaluation kit for the neuroendocrine carcinoma has the advantage that the insulin-like growth factor binding protein 2 can be used for preparing protein molecule markers for judging prognosis of the neuroendocrine carcinoma patients, thereby being of great guidance significance in postoperativemonitoring and sequential therapy of the neuroendocrine carcinoma patients.

Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor- Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.

The invention discloses an application of insulin-like growth factor binding protein 5 (IGFBP5) in promotion of mesenchymal stem cell induced periodontal tissue regeneration.

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines-1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury) / ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI / ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

The invention provides an SNP locus related to growth characteristics of patinopecten yessoensis. The locus is the 1054 site of IGFBP (Insulin Like Growth Factor Binding Proteins) genes of which the nucleotide sequence is shown as SEQ ID NO:2 and has the base of A or G. The invention also provides a probe for detecting the SNP locus and a parting primer. The transcription sequence of the IGFBP genes in the patinopecten yessoensis is subjected to sequencing and Clustal comparison, and three SNP loci are screened. The site polymorphism is detected in the patinopecten yessoensis group by using a high resolution melting curve technology, and correlation between the site genotype frequency and the growth characteristics of patinopecten yessoensis is analyzed. The locus C.1054A>G is obviously related to important growth characteristics such as the height, shell length, weight, soft weight and adductor muscle weight of the patinopecten yessoensis, the growth characteristics of the AG type individuals are obviously lower than those of AA and GG type individuals (P is less than 0.05), and the characteristic value of the GG type is the highest. Therefore, individuals of which the genotype is GG on the locus can be preferentially selected during production and are used as parents for performing high-yield patinopecten yessoensis breeding or performing large-scale breeding.

An immunoassay of proteolytic protein fragments is described, including immunoassays of proteolytic fragments of Insulin-like Growth Factor Binding Proteins (IGFBPs). In one embodiment, a sandwich-type “two-site” immunoassay involves two different recognition antibody partners, in which one antibody is specific for a proteolytic epitope of a protein fragment, and the other is specific for the protein fragment. An assay embodiment involves a first-step capturing of the protein fragment with a specific anti-protein antibody that binds to the proteolytic epitope of the protein fragment, and a second-step detection of the bound protein fragment with an antibody directed against the protein fragment. The various embodiments of the systems and methods of the invention are exemplified by immunoassays for proteolytic fragments of Insulin-like growth factor binding proteins (IGFBPs), such as IGFBP-1, IGFBP-3, and IGFBP-5.

An insulin-like growth factor binding protein 7 eukaryotic expression plasmid is disclosed. The sequence of the insulin-like growth factor binding protein 7 eukaryotic expression plasmid is shown as SEQ ID NO.2 and is named as a pIRES2-ZsGreen1-IGFBP7 eukaryotic expression vector. The insulin-like growth factor binding protein 7 eukaryotic expression plasmid can be used for preparation of cell proliferation inhibiting agents, and can be used for preparation of cell invasion inhibiting agents.

The invention relates to an insulin-like growth factor binding protein 4 mutant and pharmaceutical application thereof. According to the mutant, part of functions of natural insulin-like growth factorbinding protein are removed, in-vivo degradation caused by specific protease is avoided, and the capacity of the mutant for preventing and treating ischemic diseases by inhibiting a Wnt signal channel is improved. The mutant provided by the invention can prevent, relieve or treat ischemic diseases, and avoids various potential health risks induced by combining IGFs.